[
    [
        {
            "time": "",
            "original_text": "【民生医药|周报】原料药跑赢板块，继续推荐全球产业链定价能力强和内需驱动的医药细分龙头",
            "features": {
                "keywords": [
                    "原料药",
                    "跑赢板块",
                    "全球产业链",
                    "定价能力",
                    "内需驱动",
                    "医药细分龙头"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【民生医药|周报】原料药跑赢板块，继续推荐全球产业链定价能力强和内需驱动的医药细分龙头",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "三明联盟出手、上海“4+7”续约，仿制药价格再创新低！带量采购下，仿制药还有投资空间吗？",
            "features": {
                "keywords": [
                    "三明联盟",
                    "4+7续约",
                    "仿制药",
                    "价格新低",
                    "带量采购",
                    "投资空间"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "三明联盟出手、上海“4+7”续约，仿制药价格再创新低！带量采购下，仿制药还有投资空间吗？",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]